In people with T2DM and established (or high risk for) cardiovascular disease, multiple large cardiovascular outcome trials have shown that GLP‐1 RAs reduce the risk of major cardiovascular events (a composite outcome of cardiovascular death, non‐fatal stroke and non‐fatal myocardial infarction) [14]. This evidence concerns the gene GCG and type 2 diabetes mellitus.